Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Karen Akinsanya is recorded as Board Member at Nautilus Biotechnology, Inc. (NAUT). The proxy statement of Schrodinger, Inc. reports total compensation of $2,110,924 for Karen Akinsanya in fiscal 2025, including a base salary of $600,000. Disclosed compensation is on record for 7 fiscal years. Karen Akinsanya has spoken on 2 earnings calls across 1 company, most recently for Schrodinger, Inc. on August 5, 2026.
Summary generated from SEC filings and earnings-call records held by Equibles.
Recorded current and former roles; source labels appear when available.
2022-01-01–present
Source not stated
Recorded roles and call appearances connecting this person to public companies.
SDGR
Other people whose current roles at this company are on record from its filings.
Other people whose current roles at this company are on record from its filings.
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Schrodinger, Inc. (SDGR) | President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | $600,000 | $2,110,924 |
| 2024 | Schrodinger, Inc. (SDGR) | President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | $562,640 | $2,736,718 |
| 2023 | Schrodinger, Inc. (SDGR) | President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | $541,000 | $1,680,400 |
| 2022 | Schrodinger, Inc. (SDGR) | President of R&D, Therapeutics | $515,375 | $1,848,320 |
| 2021 | Schrodinger, Inc. (SDGR) | President of R&D, Therapeutics | $460,000 | $4,649,715 |
| 2020 | Schrodinger, Inc. (SDGR) | Executive Vice President, Chief Biomedical Scientist, Head of Discovery R&D | $400,000 | $2,330,926 |
| 2019 | Schrodinger, Inc. (SDGR) | Executive Vice President, Chief Biomedical Scientist, Head of Discovery R&D | $330,000 | $440,701 |
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
